

Yin Shi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5154457/publications.pdf>

Version: 2024-02-01

9
papers

180
citations

1478505

6
h-index

1474206

9
g-index

11
all docs

11
docs citations

11
times ranked

105
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. Lung Cancer, 2019, 138, 88-94.	2.0	54
2	Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 1649.	2.8	32
3	Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. JAMA Network Open, 2021, 4, e218065.	5.9	31
4	Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer. Advances in Therapy, 2020, 37, 2116-2126.	2.9	24
5	Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.. Oncologist, 2021, 26, e290-e297.	3.7	15
6	First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis. Cost Effectiveness and Resource Allocation, 2021, 19, 77.	1.5	15
7	Combating drug shortages in China: surveillance warning and practice standardization. International Journal of Clinical Pharmacy, 2020, 42, 309-314.	2.1	5
8	Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer. Advances in Therapy, 2020, 37, 847-859.	2.9	2
9	Establishment and Application of an Index System for the Risk of Drug Shortages in China: Based on Delphi Method and Analytic Hierarchy Process. International Journal of Health Policy and Management, 2022, , .	0.9	1